Is CBD an aphrodisiac? No human trial, one test in mice

Searches for "CBD aphrodisiac" or "CBD libido" assume that a study has compared CBD with a placebo on desire. No such study exists. A PubMed search in September 2026 crossing "cannabidiol" with "libido", "sexual desire" and "sexual function" returns no controlled trial in humans. The available data are of another kind, and each says little.

To place this gap within CBD research as a whole, our summary of what clinical studies of CBD really say lists the few indications where trials exist.

The reference work on the subject is a review published in January 2020 in Sexual Medicine Reviews by Becky Lynn and colleagues. It covers female sexual function. The authors kept twelve human research papers: eleven retrospective surveys, in which participants describe their experience after the fact, and a single prospective cohort study.

In animals, the review describes dose-dependent effects: low doses facilitate sexual behaviour or have no effect, high doses inhibit it. That work concerns THC and cannabis. The authors state that the plant's other cannabinoids have not been tested on the sexual behaviour of female rats or women. Their conclusion stays open: more studies are needed to know whether the effect is positive or negative depending on dose and species.

The figures behind the "aphrodisiac" argument come from surveys on cannabis. The most cited one was published in January 2023 in the Journal of Cannabis Research by Moser and colleagues. It questioned 811 adults online who already used cannabis. More than 70% of them reported greater desire and orgasm intensity.

Three limits prevent any conclusion about CBD. The sample selected itself, from people who were favourable to the product. The answers describe a feeling, with no control group and no physiological measurement. And the product studied is cannabis, whose psychoactive effect comes from THC. CBD does not act on the same receptors in the same way, as our comparison of THC and CBD explains. The idea that the plant's compounds reinforce each other remains a hypothesis, discussed in our article on the entourage effect.

The body makes its own cannabinoids, including anandamide (AEA) and 2-AG. A study published in 2012 in the Journal of Sexual Medicine measured their blood levels in 21 women, before and after a neutral film and then an erotic film. The more physiological and felt arousal rose, the more anandamide fell. Felt arousal also went with a fall in 2-AG.

This result shows the system takes part in the sexual response. It does not say that the system should be stimulated: arousal went together with lower endocannabinoid levels, if anything. How this system works is described in our article on the endocannabinoid system.

A study published in 2018 in Reproductive Toxicology gave oral CBD to young male mice, 21 days old at the start, for 34 consecutive days, at 15 or 30 mg/kg. At 15 mg/kg, the animals took longer to attempt a first mating and mated less often. At 30 mg/kg, the fertility rate fell by 30% and the number of litters by 23%.

These doses, given to young animals, cannot be transposed as they are to humans. But they fit a consistent picture. A 2020 review in the Journal of Applied Toxicology, which gathers 32 references, links CBD exposure to smaller testes, fewer germ cells and lower fertilisation rates in the mammals studied. Its authors consider knowledge still limited.

In March 2025, ANSES proposed classifying CBD as presumed toxic to reproduction (category 1B), citing effects on sperm production and fertility in monkeys, rats and mice. The proposal has been submitted to the European Chemicals Agency (ECHA). Our article on the classification proposed by ANSES explains the procedure.

French law leaves no room for this argument. Article L. 5111-1 of the Public Health Code makes a product a medicine as soon as it is presented as having curative or preventive properties with regard to human diseases. For a food, Regulation (EC) No 1924/2006 allows only authorised health claims, and none concerns CBD. The French Ministry of Agriculture also stated on 20 May 2026 that foods containing CBD are not authorised.

A bottle labelled "libido" therefore holds ordinary CBD sold with a claim the law does not allow. Our guide to advertising rules for CBD products lists what a brand may write. The only cannabidiol-based medicine authorised in France, Epidyolex, is prescribed for rare forms of epilepsy. A lasting loss of desire calls for a medical appointment, not a product page.